10 Overlooked Growth Stocks to Buy Now
On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Legend Biotech Corp (LEGN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 3,528 | $63,822 | 0.07% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.77 | 9,936 | $87,138.72 | 247,438 | 2026-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,922 | $541,289 | 0.02% | |
| 2. | 29,922 | $541,289 | 0.25% | |
| 3. | 12,000 | $217,080 | 0.15% | |
| 4. | 5,159 | $93,326 | 0% | |
| 5. | 2,154 | $38,962 | 0% |
News See All
RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 - Here's Why
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions
TheFly reported on February 4 that Barclays lowered its price target on LEGN to $80 from $90 and maintained an Overweight rating on the shares. Although the long-term forecast for the company's clinical...
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)
On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Legend Biotech (LEGN) Shakes Up Board
In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company...
13 Best Revenue Growth Stocks to Buy Right Now
Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss
TheFly reported on January 22 that H.C. Wainwright lowered LEGN’s price target to $50 from $60 but kept a Buy rating, noting Q4 Carvykti sales of $555M missed the $582M consensus.
Hedge Fund Resource Center